Moreover, activating STAT5B mutations have been identified in a variety of hematological neoplasms, being identified as likely driver mutations in various T cell neoplasms [14, 52, 63], with JAK3 and STAT5B in the same mutation cluster in ALL [40]. This evidence concerns the gene JAK3 and hematopoietic and lymphoid system neoplasm.